Early stage retina created from human embryonic stem cells – a world first

Article

A team of scientists at UC Irvine (UCI) in California have taken the first step in developing transplant-ready retinas by creating an eight-layer, early-stage retina from human embryonic stem cells.

A team of scientists at UC Irvine (UCI) in California have taken the first step in developing transplant-ready retinas by creating an eight-layer, early-stage retina from human embryonic stem cells.

The study's principal investigator, Hans Keirstead of the Reeve-Irvine Research Centre and the Sue and Bill Gross Stem Cell Research Centre at UCI, said: “We made a complex structure consisting of many cell types. This is a major advance in our quest to treat retinal disease.”

To create the multiple cell types the team used a differentiation technique to direct the stem cells to become specific cell types. Keirstead admitted that the engineering element presented them with the greatest challenge. Microscopic gradients had to be built for solutions to bathe the stem cells in so that specific differentiation paths could be initiated.

“Creating this complex tissue is a first for the stem cell field,” said Keirstead. “Dr Gabriel Nistor in our group addressed a really interesting scientific problem with an engineering solution, showing that gradients of solutions can create complex stem cell-based tissues.

“Creating transplantable retinas from stems cells could help millions of people and we are well on our way. ”

The researchers are reported to now be testing the early-stage retinas in animal models to learn how much they improve vision. Positive results may lead to human clinical trials.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.